http://stroke.ahajournals.org/content/47/7/1943
This article requires a subscription to view the full text. If
you have a subscription you may use the login form below to view the
article. Access to this article can also be purchased.
Abstract
Background and Purpose—Brain-derived
neurotrophic factor (BDNF) plays important roles in brain plasticity
and repair, and it influences stroke outcomes in animal models.
Circulating BDNF concentrations are lowered in patients with traumatic
brain injury, and low BDNF predicts poor recovery after this injury. We
sought to investigate whether circulating concentrations of BDNF are
altered in the acute phase of ischemic stroke and whether they are
associated with short- or long-term functional outcome.
Methods—Serum
concentrations of BDNF were measured in the Sahlgrenska Academy Study
on Ischemic Stroke. The main outcomes were modified Rankin Scale (mRS)
good (mRS score of 0–2) versus poor (mRS score of 3–6) at 3 months and 2
years after stroke, and good (mRS score of 0–2) versus poor (mRS score
of 3–5) at 7 years after stroke.
Results—Acute
concentrations of BDNF were significantly lower in ischemic stroke
cases (n=491) compared with controls (n=513). BDNF concentrations were
not significantly associated with 3-month outcome. However, patients
with BDNF in the lowest tertile had an increased risk of experiencing a
poor outcome both at 2-year and 7-year follow-up, and these associations
were independent of vascular risk factors and stroke severity (odds
ratio, 2.6; confidence intervals, 1.4–4.9; P=0.002 and odds ratio, 2.1; confidence intervals, 1.1–3.9; P=0.028, respectively).
Conclusions—Circulating
concentrations of BDNF protein are lowered in the acute phase of
ischemic stroke, and low levels are associated with poor long-term
functional outcome. Further studies are necessary to confirm these
associations and to determine the predictive value of BDNF in stroke
outcomes.
No comments:
Post a Comment